Table 3.
Change of each biological marker (from baseline to the follow-up point) depending on selected demographic and clinical variables. Multiple linear regression analysis. Abbreviations: ß, linear regression coefficient; SE, standard error; CI, Confidence interval; OL, over limit; LL, Lower limit; BMI, body mass index; DDD, defined daily dose of antipsychotic chlorpromazine equivalents; DUBM, number of days elapsed between the onset of the FEP and blood samplings; DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning scale. The bold values in the table represents the values reaching statistical significance (P<.05).
| N=53 | E-SELECTIN | |||||
|---|---|---|---|---|---|---|
| B | SE | t | CI 95% (OL) | CI 95% (LL) | p | |
| Gender (ref Female) | 1111,603 | 1894,739 | ,587 | -2714,900 | 4938,107 | ,561 |
| Age | 306,990 | 162,144 | 1,893 | -20,466 | 634,446 | ,065 |
| Cardiovascular record | -887,788 | 7850,027 | -,113 | -16741,239 | 14965,663 | ,911 |
| Lithium | 439,704 | 3230,983 | ,136 | -6085,399 | 6964,806 | ,892 |
| Antipsychotic DDD | -7,575 | 3,347 | -2,263 | -14,334 | -,816 | ,029 |
| GAF | -51,375 | 79,835 | -0,644 | -212,604 | 109,854 | ,523 |
| Cannabis consume | 36,459 | 52,865 | ,690 | -70,305 | 143,223 | ,494 |
| Cotinin consume | -11,371 | 11,689 | -,973 | -34,978 | 12,236 | ,336 |
| DUBM | 7,477 | 2,708 | 2,761 | 2,008 | 12,945 | ,009 |
| DUP | 11,219 | 12,173 | 0,922 | -13,365 | 35,802 | ,362 |
| Olanzapine+Clozapine | -2649,334 | 2501,065 | -1,059 | -7700,337 | 2401,669 | ,296 |
| ADIPONECTIN HMW | ||||||
| N=56 | B | SE | t | CI 95% (OL) | CI 95% (LL) | p |
| Gender (ref Female) | -,036 | ,618 | -,059 | -1,281 | 1,209 | ,953 |
| Age | -,021 | ,050 | -,425 | -,122 | ,080 | ,673 |
| Cardiovascular record | -0,904 | 1,638 | -,552 | -4,204 | 2,396 | ,584 |
| Lithium | -,113 | 1,027 | -,110 | -2,183 | 1,957 | ,913 |
| Antipsychotic DDD | ,001 | ,001 | 1,018 | -,001 | ,003 | ,314 |
| GAF | -,057 | ,025 | -2,272 | -,108 | -,006 | ,028 |
| Cannabis consume | -,013 | ,016 | -,826 | -,044 | ,018 | ,413 |
| Cotinin consume | ,000 | ,004 | ,112 | -,007 | ,008 | ,911 |
| DUBM | ,000 | ,001 | -,238 | -,002 | ,002 | ,813 |
| DUP | -0,004 | 0,004 | -0,972 | -0,012 | 0,004 | ,336 |
| Olanzapine+Clozapine | 0,428 | 0,777 | 0,551 | -1,138 | 1,994 | ,584 |
| ADIPONECTIN TOTAL | ||||||
| N=24 | B | SE | t | CI 95% (OL) | CI 95% (LL) | p |
| Gender (ref Female) | 2,201 | ,557 | 3,949 | 0,997 | 3,404 | ,002 |
| Age | ,094 | ,048 | 1,967 | -,009 | ,196 | ,071 |
| Cardiovascular record | 1,967 | 1,325 | 1,485 | -0,895 | 4,829 | ,161 |
| Antipsychotic DDD | -,001 | ,002 | -,781 | -,005 | ,002 | ,449 |
| GAF | -,069 | ,025 | -2,800 | -,123 | -,016 | ,015 |
| Cannabis consume | ,021 | ,025 | ,842 | -,033 | ,076 | ,415 |
| Cotinin consume | -,003 | ,006 | -,507 | -,015 | ,009 | ,621 |
| DUBM | ,003 | ,001 | 2,504 | ,000 | ,005 | ,026 |
| DUP | 0,006 | 0,003 | 1,832 | -0,001 | 0,013 | ,090 |
| Olanzapine+Clozapine | 0,288 | 1,410 | 0,205 | -2,757 | 3,333 | ,841 |
| GLYCOSYLATED HEMOGLOBLIN | ||||||
| N=52 | B | SE | t | CI 95% (OL) | CI 95% (LL) | p |
| Gender (ref Female) | -,046 | ,100 | -,465 | -0,248 | 0,155 | ,644 |
| Age | ,003 | ,009 | ,346 | -,015 | ,021 | ,731 |
| Cardiovascular record | 0,072 | 0,286 | ,252 | -0,505 | 0,650 | ,802 |
| Lithium | -,205 | 0,173 | -1,187 | -0,555 | 0,144 | ,242 |
| Antipsychotic DDD | ,000 | ,000 | -1,228 | -,001 | ,000 | ,227 |
| GAF | -,011 | ,004 | -2,883 | -,019 | -,003 | ,006 |
| Cannabis consume | -,003 | ,003 | -1,053 | -,009 | ,003 | ,299 |
| Cotinin consume | ,001 | ,001 | ,793 | -,001 | ,002 | ,432 |
| DUBM | ,000 | ,000 | ,732 | ,000 | ,000 | ,469 |
| DUP | 0,000 | 0,001 | 0,124 | -0,002 | 0,002 | ,902 |
| Olanzapine+Clozapine | -0,105 | 0,124 | -0,849 | -0,356 | 0,145 | ,401 |